WO2004058944A3 - Product quality enhancement in mammalian cell culture processes for protein production - Google Patents

Product quality enhancement in mammalian cell culture processes for protein production Download PDF

Info

Publication number
WO2004058944A3
WO2004058944A3 PCT/US2003/040939 US0340939W WO2004058944A3 WO 2004058944 A3 WO2004058944 A3 WO 2004058944A3 US 0340939 W US0340939 W US 0340939W WO 2004058944 A3 WO2004058944 A3 WO 2004058944A3
Authority
WO
WIPO (PCT)
Prior art keywords
galactose
culture
sialylation
cell culture
methods
Prior art date
Application number
PCT/US2003/040939
Other languages
French (fr)
Other versions
WO2004058944A2 (en
WO2004058944A8 (en
Inventor
Bernhard M Schilling
Scott Gangloff
Dharti Kothari
Kirk Leister
Linda Matlock
Stephen G Zegarelli
Christoph E Joosten
Jonathan O Basch
Sivakesava Sakhamuri
Steven S Lee
Original Assignee
Bristol Myers Squibb Co
Bernhard M Schilling
Scott Gangloff
Dharti Kothari
Kirk Leister
Linda Matlock
Stephen G Zegarelli
Christoph E Joosten
Jonathan O Basch
Sivakesava Sakhamuri
Steven S Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004058944(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MXPA05006522A priority Critical patent/MXPA05006522A/en
Priority to DK03808535.3T priority patent/DK1576182T4/en
Priority to EP03808535.3A priority patent/EP1576182B2/en
Priority to DE60335024T priority patent/DE60335024D1/en
Priority to BR0316882-4A priority patent/BR0316882A/en
Priority to KR1020057011764A priority patent/KR101088223B1/en
Priority to SI200331927T priority patent/SI1576182T2/en
Application filed by Bristol Myers Squibb Co, Bernhard M Schilling, Scott Gangloff, Dharti Kothari, Kirk Leister, Linda Matlock, Stephen G Zegarelli, Christoph E Joosten, Jonathan O Basch, Sivakesava Sakhamuri, Steven S Lee filed Critical Bristol Myers Squibb Co
Priority to ES03808535T priority patent/ES2354610T5/en
Priority to CA2508925A priority patent/CA2508925C/en
Priority to JP2004563950A priority patent/JP4496086B2/en
Priority to AU2003303394A priority patent/AU2003303394B2/en
Priority to AT03808535T priority patent/ATE488600T1/en
Publication of WO2004058944A2 publication Critical patent/WO2004058944A2/en
Publication of WO2004058944A3 publication Critical patent/WO2004058944A3/en
Priority to IL168873A priority patent/IL168873A/en
Publication of WO2004058944A8 publication Critical patent/WO2004058944A8/en
Priority to HK05109747.2A priority patent/HK1075474A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Abstract

The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after innoculation. Supplementation of the cultures with D-galactose, preferably in a feed medium, to sustain galactose at sialylation effective levels in the cultures until the end of a culture run reverses a decline in sialylation that accompanies culture scale up, and is advantageous for large scale culturing processes.
PCT/US2003/040939 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production WO2004058944A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES03808535T ES2354610T5 (en) 2002-12-23 2003-12-18 Improved product quality in mammalian cell culture procedures for protein production
CA2508925A CA2508925C (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production
DK03808535.3T DK1576182T4 (en) 2002-12-23 2003-12-18 PRODUCT QUALITY IMPROVEMENT BY PROCEDURE OF CULTIVATION OF PATTERN CELLS FOR PROTEIN PREPARATION
JP2004563950A JP4496086B2 (en) 2002-12-23 2003-12-18 Increasing product quality using mammalian cell culture methods for protein production
BR0316882-4A BR0316882A (en) 2002-12-23 2003-12-18 Improved product quality in mammalian cell culture processes for protein production
KR1020057011764A KR101088223B1 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production
SI200331927T SI1576182T2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production
MXPA05006522A MXPA05006522A (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production.
AT03808535T ATE488600T1 (en) 2002-12-23 2003-12-18 PRODUCT QUALITY IMPROVEMENT IN MAMMAL CELL CULTURE PROCESSES FOR PROTEIN PRODUCTION
EP03808535.3A EP1576182B2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production
DE60335024T DE60335024D1 (en) 2002-12-23 2003-12-18 PRODUCT QUALITY IMPROVEMENT IN MAMMALIAN CELL CULTURE PROCESS FOR PROTEIN PRODUCTION
AU2003303394A AU2003303394B2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production
IL168873A IL168873A (en) 2002-12-23 2005-05-30 Process for culturing cells
HK05109747.2A HK1075474A1 (en) 2002-12-23 2005-11-02 Product quality enhancement in mammalian cell culture processes for protein production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43605002P 2002-12-23 2002-12-23
US60/436,050 2002-12-23

Publications (3)

Publication Number Publication Date
WO2004058944A2 WO2004058944A2 (en) 2004-07-15
WO2004058944A3 true WO2004058944A3 (en) 2004-09-10
WO2004058944A8 WO2004058944A8 (en) 2005-07-21

Family

ID=32682324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040939 WO2004058944A2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production

Country Status (22)

Country Link
US (2) US7332303B2 (en)
EP (1) EP1576182B2 (en)
JP (1) JP4496086B2 (en)
KR (1) KR101088223B1 (en)
CN (1) CN100402660C (en)
AT (1) ATE488600T1 (en)
AU (1) AU2003303394B2 (en)
BR (1) BR0316882A (en)
CA (1) CA2508925C (en)
CO (1) CO5590971A2 (en)
CY (1) CY1111358T1 (en)
DE (1) DE60335024D1 (en)
DK (1) DK1576182T4 (en)
ES (1) ES2354610T5 (en)
HK (1) HK1075474A1 (en)
IL (1) IL168873A (en)
MX (1) MXPA05006522A (en)
PL (1) PL377603A1 (en)
PT (1) PT1576182E (en)
SI (1) SI1576182T2 (en)
TW (1) TWI328614B (en)
WO (1) WO2004058944A2 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002305716B2 (en) 2001-05-23 2007-10-25 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
CA2511520A1 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2508925C (en) * 2002-12-23 2012-08-28 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
NZ542585A (en) * 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
MXPA06001225A (en) 2003-08-04 2006-04-11 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule.
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
KR101235484B1 (en) 2005-04-06 2013-02-22 브리스톨-마이어스 스큅 컴퍼니 Methods for Treating Immune Disorders Associated with Graft Transplantaton with Soluble CTLA4 Mutant Molecules
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058567A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co FORMULATIONS OF STABLE PROTEINS
AR058568A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co METHODS TO PRODUCE A COMPOSITION WITH CTLA4-IG MOLECULES FROM A CROP MEANS
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PL2253644T3 (en) * 2005-12-20 2014-04-30 Bristol Myers Squibb Co Compositions and methods for producing a composition
EP2815768A3 (en) * 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2009539413A (en) * 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Single-chain multivalent binding protein with effector function
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
EP2091969A4 (en) * 2006-10-27 2010-05-12 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
KR20090127326A (en) 2007-03-02 2009-12-10 와이어쓰 Use of copper and glutamate in cell culture for production of polypeptides
PL2612868T3 (en) * 2007-11-01 2018-12-31 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
ES2368700T3 (en) * 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc IMMUNOTHERAPEUTIC AGENT FOR CD37 AND COMBINATION WITH A BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT OF THE SAME.
CN102037356A (en) 2008-04-22 2011-04-27 洛克菲勒大学 Methods of identifying anti-inflammatory compounds
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
JP5856845B2 (en) 2008-10-20 2016-02-10 アッヴィ・インコーポレイテッド Virus inactivation during antibody purification
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
LT2563906T (en) 2010-04-26 2018-02-26 Novartis Ag Process for cultivation of cho cells
EP2702077A2 (en) * 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9475858B2 (en) 2011-07-08 2016-10-25 Momenta Pharmaceuticals, Inc. Cell culture process
EP2809772A4 (en) * 2012-01-30 2015-06-03 Reddys Lab Ltd Dr Method for obtaining a glycoprotein composition
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2844737B1 (en) 2012-05-02 2018-03-21 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SI2867251T1 (en) 2012-06-29 2019-12-31 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
WO2014030726A1 (en) * 2012-08-23 2014-02-27 日産化学工業株式会社 Protein production accelerator
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
KR20150043523A (en) 2012-09-02 2015-04-22 애브비 인코포레이티드 Methods to control protein heterogeneity
US9512214B2 (en) * 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151878A2 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
TWI625390B (en) * 2013-03-14 2018-06-01 安美基公司 Methods for increasing mannose content of recombinant proteins
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
TWI793159B (en) * 2013-10-23 2023-02-21 美商健臻公司 Recombinant glycoproteins and uses thereof
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
ES2784775T3 (en) * 2014-01-30 2020-09-30 Coherus Biosciences Inc Perfusion media
KR20160145789A (en) 2014-04-25 2016-12-20 브리스톨-마이어스 스큅 컴퍼니 Use of ctla4 compound for achieving drug-free remission in subjects with early ra
CN106715707A (en) * 2014-06-18 2017-05-24 免疫医疗公司 Cell culture methods and media comprising n-acetylcysteine
US10544209B2 (en) 2014-10-15 2020-01-28 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
CN107969128A (en) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 Immune modulator with adjustable affinity
US20170016043A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3 binding polypeptides
JP2018536404A (en) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Method for manipulating quality characteristics of polypeptides produced in CHO cells
AU2017272349B2 (en) * 2016-06-02 2022-12-01 Klotho Therapeutics, Inc. Therapeutic recombinant klotho proteins and compositions and methods involving the same
US11932676B2 (en) 2016-11-22 2024-03-19 Klotho Therapeutics, Inc. Recombinant klotho proteins and compositions and methods involving same
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CN111321188A (en) * 2018-12-17 2020-06-23 嘉和生物药业有限公司 Formula for modifying antibody glycoform, cell culture method and application in industrial production
BR112021025769A2 (en) 2019-12-06 2022-04-12 Regeneron Pharma Anti-vegf protein compositions and methods for their production
CN113025648B (en) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Method for transient expression of target protein by Expi293 cells and application thereof
CN111676184B (en) * 2020-05-15 2021-01-29 上海多宁生物科技有限公司 Basal medium blended by supplemented medium and preparation method and application thereof
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
WO2022162700A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Cell culture methods
EP4290523A1 (en) 2021-02-08 2023-12-13 Shimadzu Corporation Estimation device, learning device, optimization device, estimation method, learning method, and optimization method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US20020001831A1 (en) * 1998-11-18 2002-01-03 Defrees Shawn Low cost manufacture of oligosaccharides

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
FR2543158B1 (en) * 1983-03-24 1985-11-15 Inst Nat Sante Rech Med MEDIUM FOR CULTURING ANIMAL CELLS WITHOUT SERUM, WITHOUT HORMONES AND WITHOUT GROWTH FACTORS AND METHODS OF PRIMARY CULTURE AND OF OBTAINING CELL LINES USING THE SAME
US5132223A (en) * 1983-11-10 1992-07-21 Thomas Jefferson University Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US4994387A (en) * 1983-11-10 1991-02-19 The Wistar Institute Process and medium for cloning and long-term serial cultivation of human endothelial cells
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
DE3801236A1 (en) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh PENTOSANE SULFATE MEDIUM
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
IL92382A (en) 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
GB9022545D0 (en) † 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5318898A (en) * 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
TW318142B (en) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69333580D1 (en) 1992-04-07 2004-09-09 Univ Michigan IMMUNE REGULATION ON THE CD28 ROUTE
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US5348877A (en) * 1993-03-12 1994-09-20 Boyce Thompson Institute For Plant Research, Inc. Method of adapting anchorage-dependent cell lines to suspension conditions
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
SE9303601D0 (en) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US5817516A (en) * 1994-04-28 1998-10-06 Boehringer Ingelheim Pharmaceuticals, Inc. Methods for proliferating and differentiating B cells with high density membrane CD40 ligand
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
WO1996030506A1 (en) * 1995-03-24 1996-10-03 Takeda Chemical Industries, Ltd. Antibody to human betacellulin and use thereof
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
EP0842425A1 (en) * 1995-07-28 1998-05-20 Beth Israel Deaconess Medical Center, Inc. A method of and test kit for mutagenesis testing
JP4306813B2 (en) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 New method for culturing animal cells
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5728580A (en) * 1996-02-20 1998-03-17 Cornell Research Foundation, Inc. Methods and culture media for inducing single cell suspension in insect cell lines
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ES2252876T5 (en) † 1997-12-03 2014-04-03 Roche Diagnostics Gmbh Process to prepare polypeptides with adequate glycolization
WO1999061650A1 (en) 1998-05-29 1999-12-02 Genentech, Inc. Cell culture process for producing glycoproteins
DE19852729A1 (en) * 1998-11-16 2000-05-18 Werner Reutter Recombinant glycoproteins, processes for their preparation, medicaments containing them and their use
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
EP1171615B1 (en) 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
WO2001059075A1 (en) 2000-02-08 2001-08-16 Genentech, Inc. Improved sialylation of glycoproteins
CA2399266A1 (en) 2000-02-08 2001-08-16 Genentech, Inc. Improved galactosylation of recombinant glycoproteins
WO2001092337A2 (en) 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU7541101A (en) * 2000-06-09 2001-12-24 Bristol Myers Squibb Co Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2001273174B2 (en) * 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
AU2002305716B2 (en) * 2001-05-23 2007-10-25 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
MXPA05000552A (en) † 2002-07-15 2005-04-28 Immunex Corp Methods and media for controlling sialylation of proteins produced by mammalian cells.
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
CA2508925C (en) * 2002-12-23 2012-08-28 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CA2511520A1 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
MXPA06001225A (en) 2003-08-04 2006-04-11 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule.
EP1979372A2 (en) * 2006-01-09 2008-10-15 Wyeth Methods of labeling transiently expressed proteins in large-scale eukaryotic cell cultures

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US20020001831A1 (en) * 1998-11-18 2002-01-03 Defrees Shawn Low cost manufacture of oligosaccharides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALTAMIRANO C. ET AL: "Decoupling cell growth and product formation in Chinese hamster ovary cells through metabolic control", BIOTECHNOL. BIOENG., vol. 76, December 2001 (2001-12-01), pages 351 - 360, XP002978219 *
DOV A.: "The bittersweet promise of glycobiology", NAT. BIOTECHNOL., vol. 19, October 2001 (2001-10-01), pages 913 - 917, XP002978266 *
WEIKERT S. ET AL: "Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins", NAT. BIOTECHNOL., vol. 17, November 1999 (1999-11-01), pages 1116 - 1121, XP002203703 *

Also Published As

Publication number Publication date
ES2354610T3 (en) 2011-03-16
KR101088223B1 (en) 2011-11-30
US20050084933A1 (en) 2005-04-21
CN100402660C (en) 2008-07-16
ES2354610T5 (en) 2020-09-14
AU2003303394B2 (en) 2009-02-19
MXPA05006522A (en) 2006-02-17
US7332303B2 (en) 2008-02-19
BR0316882A (en) 2005-10-25
TWI328614B (en) 2010-08-11
CA2508925A1 (en) 2004-07-15
EP1576182B1 (en) 2010-11-17
TW200504221A (en) 2005-02-01
JP2006511224A (en) 2006-04-06
ATE488600T1 (en) 2010-12-15
CY1111358T1 (en) 2015-08-05
JP4496086B2 (en) 2010-07-07
EP1576182A4 (en) 2007-05-02
IL168873A (en) 2013-04-30
EP1576182A2 (en) 2005-09-21
KR20050103466A (en) 2005-10-31
WO2004058944A2 (en) 2004-07-15
DE60335024D1 (en) 2010-12-30
EP1576182B2 (en) 2020-01-15
US20080070280A1 (en) 2008-03-20
CO5590971A2 (en) 2005-12-30
CA2508925C (en) 2012-08-28
AU2003303394A1 (en) 2004-07-22
DK1576182T3 (en) 2011-02-21
PT1576182E (en) 2011-01-21
SI1576182T2 (en) 2020-07-31
HK1075474A1 (en) 2005-12-16
CN1820080A (en) 2006-08-16
SI1576182T1 (en) 2011-01-31
DK1576182T4 (en) 2020-04-20
PL377603A1 (en) 2006-02-06
WO2004058944A8 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2004058944A8 (en) Product quality enhancement in mammalian cell culture processes for protein production
TW200512297A (en) Mammalian cell culture processes for protein production
Ljunggren et al. Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures
WO2002101019A3 (en) Methods of culturing animal cells and polypeptide production in animal cells
HK1080115A1 (en) Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom e1-
PL376381A1 (en) Methods and media for controlling sialylation of proteins produced by mammalian cells
GB2429211A (en) Feeder independent extended culture of embryonic stem cells
UA92157C2 (en) Process for production of growth hormone
MX2012003654A (en) Methods of production of glycoproteins in mammalian cell cultures using glucocorticoids.
CA2240097A1 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
WO2005028626A3 (en) Cell culture media
PL1623019T5 (en) Restricted glucose feed for animal cell culture
EP1835022A4 (en) Cell culture method and utilization of the same
EP3495491A1 (en) Method for producing recombinant protein
Milne et al. Functional expression of a heterologous nickel-dependent, ATP-independent urease in Saccharomyces cerevisiae
WO2000056905A3 (en) Method for enhancing and/or improving plant growth and/or yield or modifying plant architecture
Castañón-Rodríguez et al. Effects of oxygen and nutrients on xylitol and ethanol production in sugarcane bagasse hydrolyzates
WO2007056062A3 (en) Methods for adapting mammalian cells
NZ515762A (en) Method of producing a heparin-binding protein by expressing it in a mammalian cell that can be cultured in anaerobic conditions
DE59911877D1 (en) METHOD FOR IMPROVING THE TRANSFER OF GENETIC MATERIAL IN MAMMALIAN CELLS BY USING P21 (WAF-1)
GB9828624D0 (en) Production of proteins
RU2008100689A (en) METHOD FOR PRODUCING PROTEIN HYDROLYSIS
WO2004087860A3 (en) Materials and methods for regulating process formation in cell culture
Gao et al. Lactic Acid Fermentation with the Supplementation of Fish Wastes
UA81564C2 (en) Method for differentiation of human stromal stem cells in cultural medium in vitro

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 168873

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2517/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006522

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003808535

Country of ref document: EP

Ref document number: 1020057011764

Country of ref document: KR

Ref document number: 05061313

Country of ref document: CO

Ref document number: 2508925

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 377603

Country of ref document: PL

Ref document number: 2003303394

Country of ref document: AU

Ref document number: 2004563950

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2004 UNDER (72, 75) ADD "LEE, STEVEN, S. ¢US/US!; 9105WHISTLING SWAN LANE, MANLIUS, NY 13104 (US)"

WWE Wipo information: entry into national phase

Ref document number: 20038A99353

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003808535

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316882

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020057011764

Country of ref document: KR